» Articles » PMID: 37063886

Machine Learning-based Identification of Tumor-infiltrating Immune Cell-associated Model with Appealing Implications in Improving Prognosis and Immunotherapy Response in Bladder Cancer Patients

Overview
Journal Front Immunol
Date 2023 Apr 17
PMID 37063886
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Immune cells are crucial components of the tumor microenvironment (TME) and regulate cancer cell development. Nevertheless, the clinical implications of immune cell infiltration-related mRNAs for bladder cancer (BCa) are still unclear.

Methods: A 10-fold cross-validation framework with 101 combinations of 10 machine-learning algorithms was employed to develop a consensus immune cell infiltration-related signature (IRS). The predictive performance of IRS in terms of prognosis and immunotherapy was comprehensively evaluated.

Results: The IRS demonstrated high accuracy and stable performance in prognosis prediction across multiple datasets including TCGA-BLCA, eight independent GEO datasets, our in-house cohort (PUMCH_Uro), and thirteen immune checkpoint inhibitors (ICIs) cohorts. Additionally, IRS was superior to traditional clinicopathological features (e.g., stage and grade) and 94 published signatures. Furthermore, IRS was an independent risk factor for overall survival in TCGA-BLCA and several GEO datasets, and for recurrence-free survival in PUMCH_Uro. In the PUMCH_Uro cohort, patients in the high-IRS group were characterized by upregulated CD8A and PD-L1 and TME of inflamed and immunosuppressive phenotypes. As predicted, these patients should benefit from ICI therapy and chemotherapy. Furthermore, in the ICI cohorts, the high-IRS group was related to a favorable prognosis and responders have dramatically higher IRS compared to non-responders.

Conclusions: Generally, these indicators suggested the promising application of IRS in urological practices for the early identification of high-risk patients and potential candidates for ICI application to prolong the survival of individual BCa patients.

Citing Articles

Targeting the Tumor Microenvironment in EGFR-Mutant Lung Cancer: Opportunities and Challenges.

Lim J, Jung J, Kim Y, Kim C, Lee S, Park D Biomedicines. 2025; 13(2).

PMID: 40002883 PMC: 11852785. DOI: 10.3390/biomedicines13020470.


Predicting distant metastasis of bladder cancer using multiple machine learning models: a study based on the SEER database with external validation.

Zou X, Rao X, Huang J, Zhou J, Chao Chao H, Zeng T Front Oncol. 2024; 14:1477166.

PMID: 39735606 PMC: 11681425. DOI: 10.3389/fonc.2024.1477166.


Analysis of Lymphovascular Infiltration and Tumor-Associated Macrophages in Cervical Cancer Immunoescape.

Guan L, Xu X, Xu J, Xu G, Zhang Y, Xia H Onco Targets Ther. 2024; 17:1117-1136.

PMID: 39583248 PMC: 11585989. DOI: 10.2147/OTT.S468484.


Advanced machine learning unveils CD8 + T cell genetic markers enhancing prognosis and immunotherapy efficacy in breast cancer.

Ma H, Shi L, Zheng J, Zeng L, Chen Y, Zhang S BMC Cancer. 2024; 24(1):1222.

PMID: 39354417 PMC: 11446097. DOI: 10.1186/s12885-024-12952-w.


Revealing the mechanisms of RAC3 in tumor aggressiveness, the immunotherapy response, and drug resistance in bladder cancer.

Gao H, Qiu Y, Zheng X, Xu T, Liu G Front Oncol. 2024; 14:1466319.

PMID: 39351351 PMC: 11441374. DOI: 10.3389/fonc.2024.1466319.


References
1.
Necchi A, Anichini A, Raggi D, Briganti A, Massa S, Luciano R . Pembrolizumab as Neoadjuvant Therapy Before Radical Cystectomy in Patients With Muscle-Invasive Urothelial Bladder Carcinoma (PURE-01): An Open-Label, Single-Arm, Phase II Study. J Clin Oncol. 2018; 36(34):3353-3360. DOI: 10.1200/JCO.18.01148. View

2.
Leek J, Johnson W, Parker H, Jaffe A, Storey J . The sva package for removing batch effects and other unwanted variation in high-throughput experiments. Bioinformatics. 2012; 28(6):882-3. PMC: 3307112. DOI: 10.1093/bioinformatics/bts034. View

3.
Ramakrishnan R, Gabrilovich D . Novel mechanism of synergistic effects of conventional chemotherapy and immune therapy of cancer. Cancer Immunol Immunother. 2013; 62(3):405-10. PMC: 11029489. DOI: 10.1007/s00262-012-1390-6. View

4.
Chen H, Pan Y, Jin X, Chen G . Identification of a Four Hypoxia-Associated Long Non-Coding RNA Signature and Establishment of a Nomogram Predicting Prognosis of Clear Cell Renal Cell Carcinoma. Front Oncol. 2021; 11:713346. PMC: 8353455. DOI: 10.3389/fonc.2021.713346. View

5.
Zhang Z, Chen L, Chen H, Zhao J, Li K, Sun J . Pan-cancer landscape of T-cell exhaustion heterogeneity within the tumor microenvironment revealed a progressive roadmap of hierarchical dysfunction associated with prognosis and therapeutic efficacy. EBioMedicine. 2022; 83:104207. PMC: 9382263. DOI: 10.1016/j.ebiom.2022.104207. View